Could This Tiny Device Help You Make an Extra $30k a Year?

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

Vikas Sinha Biography and Net Worth

CFO of Alexion Pharmaceuticals

Vikas Sinha brings more than 25 years of experience in executive finance roles in the life sciences industry. He is CFO and co-founder of ElevateBio and also serves as President and CFO of AlloVir, an ElevateBio portfolio company.

Prior to ElevateBio, Vikas served as CFO of Alexion Pharmaceuticals for 11 years, where he was responsible for finance, business development, strategy and IT. During his tenure as CFO, Alexion’s market cap grew from $600 million to more than $30 billion and revenue grew from zero to more than $3 billion.
‍
Prior to joining Alexion, Vikas held various positions with Bayer AG in the United States, Japan, Germany, and Canada, including Vice President and CFO of Bayer Pharmaceuticals Corporation, USA, Vice President and Chief Financial Officer of Bayer Yakuhin Ltd., in Japan. He serves as an independent board member and Audit Committee chair of Verona Pharma Inc.

Vikas received his M.B.A. from the Asian Institute of Management, Manila, Philippines. He is a qualified Chartered Accountant and associate member of the Institute of Chartered Accountants of India and a Certified Public Accountant in the United States.

What is Vikas Sinha's net worth?: The estimated net worth of Vikas Sinha is at least $208.21 million as of November 19th, 2024. Mr. Sinha owns 1,140,894 shares of Alexion Pharmaceuticals stock worth more than $208,213,155 as of December 23rd. This net worth evaluation does not reflect any other assets that Mr. Sinha may own. Learn More about Vikas Sinha's net worth.
How do I contact Vikas Sinha?: The corporate mailing address for Mr. Sinha and other Alexion Pharmaceuticals executives is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. Alexion Pharmaceuticals can also be reached via phone at 475-230-2596 and via email at [email protected]. Learn More on Vikas Sinha's contact information.
Has Vikas Sinha been buying or selling shares of Alexion Pharmaceuticals?: Vikas Sinha has not been actively trading shares of Alexion Pharmaceuticals over the course of the past ninety days. Most recently, Vikas Sinha sold 277 shares of the business's stock in a transaction on Monday, August 8th. The shares were sold at an average price of $137.14, for a transaction totalling $37,987.78. Following the completion of the sale, the chief financial officer now directly owns 178,463 shares of the company's stock, valued at $24,474,415.82. Learn More on Vikas Sinha's trading history.
Who are Alexion Pharmaceuticals' active insiders?: Alexion Pharmaceuticals' insider roster includes Daniel Bazarko (CAO), Tanisha Carino (CAO), Paul Clancy (CFO), Indrani Franchini (EVP), Ludwig Hantson (CEO & Director), John Orloff (EVP), Vikas Sinha (CFO), and Heidi Wagner (SVP). Learn More on Alexion Pharmaceuticals' active insiders.

Vikas Sinha Insider Trading History at Alexion Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/8/2016	Sell	277	$137.14	$37,987.78	178,463
2/29/2016	Sell	1,122	$138.91	$155,857.02	179,862
2/8/2016	Sell	6,547	$140.04	$916,841.88	171,862
2/10/2015	Sell	1,985	$171.15	$339,732.75
2/9/2015	Sell	2,703	$174.18	$470,808.54
2/4/2015	Sell	1,571	$174.19	$273,652.49
12/18/2014	Sell	5,493	$182.08	$1,000,165.44
12/3/2014	Sell	75,000	$198.96	$14,922,000.00
11/3/2014	Sell	49,307	$192.63	$9,498,007.41
8/4/2014	Sell	1,525	$157.82	$240,675.50
2/4/2014	Sell	3,552	$154.47	$548,677.44	129,775
10/28/2013	Sell	50,000	$122.97	$6,148,500.00
2/4/2013	Sell	3,483	$95.81	$333,706.23

Vikas Sinha Buying and Selling Activity at Alexion Pharmaceuticals

Alexion Pharmaceuticals Company Overview

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $182.50

$182.50

50 Day Range

MA: $182.82

$179.45

$186.61

2 Week Range

Now: $182.50

$99.91

$187.45

Volume

10 shs

Average Volume

3,309,941 shs

Market Capitalization

$40.34 billion

P/E Ratio

59.64

Dividend Yield

N/A

Beta

1.25

How Low-Cost Stocks Generate Monthly Income

From Darwin | Ad

Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!

👉 Yes, I Want the Free Report! 👈